<DOC>
	<DOCNO>NCT00313287</DOCNO>
	<brief_summary>The purpose study determine safety efficacy 30 mg daily dose clevudine ( L-FMAU ) 24 week treatment patient chronic HBV .</brief_summary>
	<brief_title>Safety Antiviral Activity Study Clevudine 30 mg QD Patient With Chronic HBV</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>1 . Patients 18 60 , inclusive . 2 . Patients HBV DNA ³1 x 106 copies/mL within 30 day baseline . 3 . Patients document HBsAg positive &gt; 6 month . ( The documentation positive HBsAg previous 6 month include previous laboratory report HBsAg positive HBeAg positive least 6 month ago IgM antiHBc negative IgG antiHBc positive screening ) . 4 . Patients HBeAg positive . 5 . Patients ALT level range ≥1.2 &lt; 15 time upper limit normal ( x ULN ) bilirubin level less 2.0 mg/dL , prothrombin time le 1.7 ( INR ) , serum albumin level least 3.5 g/dL . 6 . Women child bear potential negative serum ( βHCG ) pregnancy test take within 14 day start therapy . 7 . Patients able give write informed consent prior study start comply study requirement . 1 . Patients currently receive antiviral , immunomodulatory corticosteroid therapy . 2 . Patients previously treat lamivudine , lobucavir , famciclovir , adefovir investigational nucleoside HBV infection . 3 . Previous treatment interferon end less 6 month prior screen visit . 4 . Patients history ascites , variceal hemorrhage hepatic encephalopathy . 5 . Patients coinfected HCV , HDV HIV . 6 . Patients clinical evidence liver mass alphafetoprotein &gt; 50 ng/mL 7 . Patients pregnant breastfeeding . 8 . Patients unwilling use `` effective '' method contraception treatment 3 month cessation therapy . For male , condom use . Females surgically sterile ( via hysterectomy bilateral tubal ligation ) postmenopausal use least medically acceptable barrier method contraception ( i.e . IUD , barrier method spermicide abstinence ) 9 . Patients clinically relevant history abuse alcohol drug . 10 . Patients significant gastrointestinal , renal , hepatic ( decompensated ) , bronchopulmonary , biliary disease except asymptomatic GB stone , neurological , cardiovascular , oncologic allergic disease . The patient benign tumor exclude judged investigator continuation study would interfere benign tumor . 11 . Patients creatinine clearance le 60mL/min estimate follow formula : ( 140age year ) ( body weight [ kg ] ) ( 72 ) ( serum creatinine [ mg/dL ] ) [ Note : multiply estimate 0.85 woman ] Patients find YMDD HBV DNA polymerase mutation baseline exclude overall efficacy evaluation analyze separately . They include overall safety evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2006</verification_date>
</DOC>